The acquisition will provide Gilead, MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator.
Lead Product(s): MB272
Therapeutic Area: Immunology Product Name: MB272
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $405.0 million Upfront Cash: $405.0 million
Deal Type: Acquisition August 04, 2022
Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of NT-0167 through clinical development.
Lead Product(s): NT-0167
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 03, 2020